FDA Grants Seventh Approval under the National Priority Voucher Pilot Program

View source ↗

Summary

FDA grants seventh approval under the National Priority Voucher Pilot Program for Bizengri (zenocutuzumab-zbco) to treat NRG1 fusion-positive cholangiocarcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• BIZENGRI (ZENOCUTUZUMAB)

Snippet

FDA issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.